Acasti Pharma, Inc. (NASDAQ:ACST) Q4 2022 Earnings Conference Call June 21, 2022 1:00 PM ET

Company Participants

Robert Blum - Investor Relations

Jan D'Alvise - President and Chief Executive Officer

Brian Ford - Chief Financial Officer

Monique Champagne - Vice President, Clinical Affairs

Conference Call Participants

Leland Gershell - Oppenheimer

Operator

Good day, and welcome to the Acasti Pharma Fourth Quarter and Fiscal Year 2022 Financial Results Conference Call. All participants will be in listen-only mode. [Operator Instructions] After today's presentation, there will be an opportunity to ask questions. [Operator Instructions] Please note this event is being recorded.

I would now like to turn the conference over to Robert Blum of Lytham Partners. Please go ahead.

Robert Blum

All right. Thank you very much MJ and welcome to Acasti Pharma’s fiscal year and 2022 conference call. On the call with us this afternoon is, Jan D'Alvise, President and Chief Executive Officer; Brian Ford, Chief Financial Officer; and Monique Champagne, Vice President of Clinical Affairs. Following management’s prepared remarks, there will a Q&A session. Should any questions remain after the call, please don’t hesitate to contact me at 602-889-9700.

I'd also like to remind everyone that statements on this conference call that are not statements of historical or current facts constitute forward-looking information within the meaning of the Canadian Securities Laws and forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and the Securities and Exchange act 1934.

Such forward-looking statements involve known and unknown risks and uncertainties that could cause the actual results to be materially different from those expressed or implied by such forward-looking statements.

In addition to statements which explicitly describes such risks and uncertainties, listeners are urged to consider statements labeled with terms belief, expects, intends, anticipates, potential, should, may, will, plans, continue, targeted or other similar expressions to be uncertain and forward-looking. Listeners are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this conference call.

Forward-looking statements during this conference call may include, but are not limited to the success and timing of regulatory submissions of the planned Phase 3 study for GTX104 and Acasti’s other pre-clinical and clinical trials, regulatory requirements or developments and the outcome of meetings with the FDA, changes to clinical trial designs and regulatory pathways, legislative, regulatory, political and economic developments and cost associated with Acasti’s clinical trials.